Navigation Links
GeneNews provides Centocor access to its osteoarthritis program
Date:12/11/2008

TORONTO, Dec. 11 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has entered into a agreement allowing Centocor Research & Development, Inc. selected access to research from its osteoarthritis genomic biomarker program. Additional terms of the agreement were not disclosed.

"The Sentinel Principle(TM), our proprietary platform technology for the discovery of blood-based biomarkers, was validated around osteoarthritis, a debilitating joint disease," said Dr. Heiner Dreismann, Lead Director and Interim CEO of GeneNews. "This agreement is a positive reflection of the quality of our research and technology and a source of non-dilutive funding that will contribute to our commercialization efforts."

    About GeneNews
    --------------

GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. For more information on GeneNews, visit www.genenews.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE GeneNews Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeneNews to exhibit ColonSentry(TM) at Family Medicine Forum 2008
2. GeneNews rolls out ColonSentry(TM) test in additional Toronto area labs
3. GeneNews appoints Canadian Colorectal Cancer Advisory Board
4. GeneNews restructures operations
5. GeneNews appoints Patrick Terry as lead strategic advisor for U.S. commercialization of ColonSentry(TM)
6. GeneNews Announces Second Quarter Results
7. GeneNews launches worlds first blood test for colorectal cancer screening
8. GeneNews announces management changes to support commercialization of ColonSentry(TM)
9. Genenews adds two members to its Board of Directors
10. GeneNews Announces First Quarter Results
11. GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017  OncoSec Medical Incorporated ... immunotherapies, will host a Key Opinion Leader event to ... an oral and poster presentation at the upcoming 2017 ... The KOL event will be held in-person and via ... EST / 9:00 AM PST at the Lotte New ...
(Date:2/23/2017)... RAFAEL, Calif., Feb. 23, 2017 ... U.S. dollars, except per share data, unaudited)Three Months Ended ... ChangeTotal BioMarin Revenue $   ...   22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... The Fight Against Cancer Innovation Trust (FACIT) and the ... report that Fusion Pharmaceuticals Inc. (Fusion) has closed a ... – JJDC, Inc. (JJDC) as the lead investor. Additional, ... and Genesys Capital, as well as founding investor FACIT.  ... ...
(Date:2/23/2017)... Atlanta, it seems everyone has a chance to express their ... expressive and dynamic community unlike any other. The businesses that ... With their newest salon in ... on that tradition with a unique, fresh approach to head ... the newest of 13 nationwide locations, each of them well-situated ...
Breaking Biology Technology:
(Date:2/8/2017)... (NASDAQ: AWRE ), a leading supplier of biometrics ... and year ended December 31, 2016. Revenue ... to $6.9 million in the same quarter last year. Operating ... compared to $2.6 million in the fourth quarter of 2015. ... million, or $0.02 per diluted share, which compares to $1.8 ...
(Date:2/7/2017)... Feb. 7, 2017   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... its innovative, highly flexible and award winning eClinical solution, ... iMedNet is a proven Software-as-a-Service (SaaS) clinical ... Capture (EDC), but also delivers an entire suite of ...
(Date:2/3/2017)...  Texas Biomedical Research Institute announced that its Board of ... as the Institute,s new President and CEO. Dr. Schlesinger will ... He is currently the Chair of the Department of Microbial ... Interface Biology at Ohio State University. "We are ... CEO of Texas Biomed," said Dr. James O. Rubin ...
Breaking Biology News(10 mins):